CompletedPhase 1NCT04049825

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Studying Diffuse large B-cell lymphoma with chronic inflammation

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Otsuka Pharmaceutical Co., Ltd.
Principal Investigator
Nobuhito Sanada
Otsuka Pharmaceutical Co., Ltd.
Intervention
OPB-111077(drug)
Enrollment
36 target
Eligibility
20-80 years · All sexes
Timeline
20192026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04049825 on ClinicalTrials.gov

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

See all trials for Diffuse large B-cell lymphoma with chronic inflammation

← Back to all trials